29 December 2023 in Pediatric Neurology
1 September 2025 in Journal of Child Neurology
New daily persistent headache is a chronic, treatment-resistant primary headache disorder with limited guidance on effective management. Despite its significant impact on headache-related quality of life, few studies have identified targeted therapies that contribute to symptom resolution. This study aims to describe the outcomes of pediatric patients diagnosed with new daily persistent headache and assess associations between specific interventions and headache resolution. A retrospective review was conducted using data from a patient registry at Children's National Hospital. Patients diagnosed with new daily persistent headache were included. Demographic characteristics, clinical features, prior treatments, and resolution rates were analyzed. Statistical comparisons were made between patients who experienced headache resolution and those with persistence of headache. A total of 182 pediatric patients were included (mean age: 15.5 years; 78% female). Headache resolution occurred in 47 patients (25.8%). For patients whose new daily persistent headache resolved, coenzyme Q10 (CoQ10) supplementation was the only treatment that reached statistical significance, being more frequently administered in the resolved group compared with the nonresolved group (17% vs 4%, P = .010). Additional treatments approaching statistical significance during resolution of new daily persistent headache included magnesium ( P = .086), topiramate ( P = .112), and onabotulinum toxin A injections ( P = .179). Patients who engaged in regular exercise showed a trend toward higher resolution rates ( P = .058). CoQ10 supplementation may play a role in new daily persistent headache resolution, with potential benefit from exercise, magnesium, topiramate, and onabotulinum toxin A injections approaching significance. Further prospective studies and randomized controlled trials are needed to establish causality and optimize treatment strategies for pediatric new daily persistent headache.
19 June 2026 in SSRN Electronic Journal
Background: Peripheral nerve blocks (PNBs), while an effective treatment of headache disorders in adults, have been infrequently studied in pediatric patients. This study aimed to assess practice patterns in PNB use in pediatric headache.Methods: This was a prospective study conducted between 2020 and 2022 in a headache clinic at a tertiary children’s hospital. Pre- and post-injection survey data were prospectively obtained from 16 patients over 32 visits where PNBs, including greater and lesser occipital, auriculotemporal, supraorbital, and supratrochlear nerve blocks, were administered.Results: Participants ranged in age from 10 to 19 years old, with a median age of 16.7 years, and the majority were diagnosed with migraine without aura. Among the total cohort, mean pain scores, obtained on a 10-point scale, decreased from 4.4 pre-injection to 2.8 post-injection (p=0.003). When stratified by specific headache diagnosis, only patients with migraine without aura reported significant pain decrease (p=0.007).Conclusion: These preliminary findings support that PNBs may be a promising treatment in pediatric headache, particularly in migraine without aura.
9 July 2026 in Pediatric Neurology
17 October 2026 in Pediatric Neurology